Tesla takes a quarter of Norway electric market

Tesla Motor's Model S electric sports car has taken a 25 percent chunk of Norway's booming electric car market, selling nearly 2,000 vehicles in 2013.

Tesla takes a quarter of Norway electric market
Nissan Leafs at a charging point in Norway: NTB Scanpix
The sales, most of which came in the last three months of the year, come after the luxury electric car maker sold just 32 cars in 2012. 
Norway is now Tesla's most largest overseas market, with sales powered by the country's combination of wealth and generous incentives for electric vehicles. 
Sales of electric cars in Norway nearly doubled in 2013, with the best selling electric vehicle, the Nissan Leaf, ending the year as the country's third best-selling car. 
According to data from Norwegian road user's group OFW, Nissan sold 4,604 Leafs over the year, making up 58 percent of the 7,882 electric cars sold over the year. 
This put it just behind the Toyota Auris and the Volkswagen Golf, the country's best-selling car. 
The Model S, which was Norway's best-selling car in September, due to the filling of a back-log of orders, ended the year in 20th place. 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.


Norway to send 200,000 AstraZeneca doses to Sweden and Iceland

Norway, which has suspended the use of AstraZeneca's Covid vaccine until further notice, will send 216,000 doses to Sweden and Iceland at their request, the Norwegian health ministry said Thursday.

Norway to send 200,000 AstraZeneca doses to Sweden and Iceland
Empty vials of the AstraZeneca vaccine. (Photo by GABRIEL BOUYS / AFP)

“I’m happy that the vaccines we have in stock can be put to use even if the AstraZeneca vaccine has been paused in Norway,” Health Minister Bent Høie said in a statement.

The 216,000 doses, which are currently stored in Norwegian fridges, have to be used before their expiry dates in June and July.

Sweden will receive 200,000 shots and Iceland 16,000 under the expectation they will return the favour at some point. 

“If we do resume the use of the AstraZeneca vaccine, we will get the doses back as soon as we ask,” Høie said.

Like neighbouring Denmark, Norway suspended the use of the AstraZeneca jab on March 11 in order to examine rare but potentially severe side effects, including blood clots.

Among the 134,000 AstraZeneca shots administered in Norway before the suspension, five cases of severe thrombosis, including three fatal ones, had been registered among relatively young people in otherwise good health. One other person died of a brain haemorrhage.

On April 15, Norway’s government ignored a recommendation from the Institute of Public Health to drop the AstraZeneca jab for good, saying it wanted more time to decide.

READ MORE: Norway delays final decision on withdrawal of AstraZeneca vaccine 

The government has therefore set up a committee of Norwegian and international experts tasked with studying all of the risks linked to the AstraZeneca and Johnson & Johnson vaccines, which is also suspected of causing blood clots.

Both are both based on adenovirus vector technology. Denmark is the only European country to have dropped the AstraZeneca
vaccine from its vaccination campaign, and said on Tuesday it would “lend” 55,000 doses to the neighbouring German state of Schleswig-Holstein.